Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) will host an investor webcast on Monday, June 29, 2026, at 7:45 a.m. ET.
The event will cover updates on the nomlabofusp clinical development program for Friedreich’s ataxia, including a regulatory update and data from an ongoing long-term open-label study. An archived webcast will be available afterward on Larimar’s website.
Positive
- None.
Negative
- None.
News Market Reaction – LRMR
In the Jun 29 session, LRMR declined 12.57%, reflecting a significant negative market reaction. Argus tracked a peak move of +20.1% during that session. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Earnings & update | Positive | -5.1% | Q1 2026 results, nomlabofusp progress, rolling BLA and strong cash runway. |
| Apr 30 | Clinical data | Positive | -3.0% | Cross‑species FXN data supporting skin FXN as surrogate endpoint for FA. |
| Mar 19 | Earnings & pipeline | Positive | +4.0% | FY 2025 results, Breakthrough Therapy status and timelines toward BLA and launch. |
| Mar 04 | Investor conferences | Neutral | -4.2% | Participation in two March 2026 healthcare investor conferences with webcast replays. |
| Feb 25 | Equity offering | Negative | -7.2% | Upsized $100M public equity offering to fund nomlabofusp and operations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
LRMR has often traded lower on otherwise positive pipeline and financing updates, showing a tendency toward cautious reactions to good news.
Key Terms
open label medical
friedreich’s ataxia medical
clinical-stage medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Webcast on Monday, June 29, 2026, at 7:45 am ET
BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.
Webcast Details
To access the webcast on Monday, June 29, 2026, at 7:45 am EDT, please visit this link to the event. Following the live event, an archived webcast will be available on the “Events & Presentations” page of the Larimar website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for adults and children with Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding the timing of the BLA submission, the expectations of the timing of, and potential for, accelerated approval or accelerated access, time to launch and market and overall development plans and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target”, “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA and Larimar’s ability to timely implement the revised dosing regimen in its clinical program for nomlabofusp; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; that the FDA may not ultimately agree with Larimar’s rolling BLA submission strategy; Larimar’s ability to submit BLA modules on the intended timelines; Larimar’s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; the timing of any potential commercial launch of nomlabofusp, if approved; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
